S&P Futures
4,704.00 +2.50 (+0.05%) Dow Futures
35,830.00 +19.00 (+0.05%) Nasdaq Futures
16,494.75 +13.50 (+0.08%) Russell 2000 Futures
2,365.40 +1.20 (+0.05%) Gold
1,861.20 -0.20 (-0.01%) Silver
24.88 -0.02 (-0.08%)
Rubius Therapeutics, Inc. (RUBY)
Chart Events
Performance Outlook
| Previous Close | 13.49 |
| Open | 13.63 |
| Bid | 13.00 x 800 |
| Ask | 13.75 x 900 |
| Day's Range | 13.02 - 13.68 |
| 52 Week Range | 6.21 - 38.71 |
| Volume | |
| Avg. Volume | 300,300 |
| Market Cap | 1.206B |
| Beta (5Y Monthly) | 2.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.40 |
- GlobeNewswire
Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on No
- GlobeNewswire
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
U.S. FDA Recently Cleared Investigational New Drug Application for RTX-224CAMBRIDGE Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the poster presentation of preclinical data for RTX-224, a broad immune costimulatory ago
- GlobeNewswire
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update at the Jefferies London Healthcare Conference via a virtual pr
